

University of California in San Diego Women in Medicine and iGIANT Roundtable

Discussion Points

1. While **advancements have** been made, there remains a discrepancy in female representation, including of pregnant and breastfeeding women, within **clinical trials**. It is essential for the literature to be **more inclusive of diverse patient populations**.
2. **Marketing of medications** may overrepresent female patients versus male patients, which may potentially result in lower prescribing of these medications for diverse populations.
3. As clinicians, it is important to be aware of how women may have **clinical presentations** and **risk factors** for diseases which can differ compared to men, and how lack of recognition of these factors may lead to underdiagnosis and undertreatment for women.
4. Consideration of the **differences in the efficacy and side effects of different medications** among men and women is essential in providing high quality care.
5. It is important to **be aware of our own implicit and conscious biases** to prevent disparate care to individuals across the sex/gender spectrum.

Calls To Action

1. We will incorporate a sex/gender lens within **medical education**, including in teaching conferences, medical student and resident lectures, and examinations.
2. We will be more mindful of sex/gender disparities when **reading and evaluating the literature** before deriving conclusions from the data.
3. When **conducting basic science and clinical research studies**, including in drug development, we will ensure that the study population is **representative of patient diversity**, including sex/gender differences.
4. We will routinely assess **medication dosages and side effects** employing a sex/gender lens, with an understanding of potential differences in pharmacokinetics and pharmacodynamics between male and female patients.
5. Among healthcare workers, we will increase awareness regarding potential sex/gender differences in **personal protective equipment, medical equipment**, and other **technologies and devices**.